VIPoma MRI: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
{{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}}
{{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}}
==Overview==
==Overview==
Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI.
[[Abdominal]] [[MRI]] is helpful in the [[diagnosis]] of VIPoma. On [[abdominal]] [[MRI]], VIPoma is characterized by a [[mass]] which is hypointense on [[T1]]-weighted [[MRI]] and hyperintense on T2-weighted [[MRI]].
==MRI==
==MRI==
*Findings on abdominal MRI suggestive of VIPoma include:<ref name="SofkaSemelka1997">{{cite journal|last1=Sofka|first1=Carolyn M.|last2=Semelka|first2=Richard C.|last3=Marcos|first3=Hani B.|last4=Woosley|first4=John T.|title=MR Imaging of metastatic pancreatic VIPoma|journal=Magnetic Resonance Imaging|volume=15|issue=10|year=1997|pages=1205–1208|issn=0730725X|doi=10.1016/S0730-725X(97)00201-4}}</ref><ref name="Reidy-LagunesGollub2011">{{cite journal|last1=Reidy-Lagunes|first1=Diane L.|last2=Gollub|first2=Marc J.|last3=Saltz|first3=Leonard B.|title=Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?|journal=Journal of Clinical Oncology|volume=29|issue=3|year=2011|pages=e74–e75|issn=0732-183X|doi=10.1200/JCO.2010.32.8559}}</ref>
*Findings on [[abdominal]] [[Magnetic resonance imaging|MRI]] suggestive of VIPoma include:<ref name="SofkaSemelka1997">{{cite journal|last1=Sofka|first1=Carolyn M.|last2=Semelka|first2=Richard C.|last3=Marcos|first3=Hani B.|last4=Woosley|first4=John T.|title=MR Imaging of metastatic pancreatic VIPoma|journal=Magnetic Resonance Imaging|volume=15|issue=10|year=1997|pages=1205–1208|issn=0730725X|doi=10.1016/S0730-725X(97)00201-4}}</ref><ref name="Reidy-LagunesGollub2011">{{cite journal|last1=Reidy-Lagunes|first1=Diane L.|last2=Gollub|first2=Marc J.|last3=Saltz|first3=Leonard B.|title=Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?|journal=Journal of Clinical Oncology|volume=29|issue=3|year=2011|pages=e74–e75|issn=0732-183X|doi=10.1200/JCO.2010.32.8559}}</ref>
**T1-weighted MRI: hypointense signal
**[[T1]]-weighted [[MRI]]: hypointense signal
**T2-weighted MRI: hyperintense signal
**T2-weighted [[MRI]]: hyperintense signal
*MRI with gadolinium enhancement is more sensitive compared to CT scan in diagnosis of liver metastases which are shown as peripheral ring enhancement.
*[[MRI]] with [[gadolinium]] enhancement is more sensitive compared to [[CT scan]] in [[diagnosis]] of [[liver]] [[metastases]] which are shown as peripheral ring enhancement.


==References==
==References==
Line 16: Line 16:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Primary care]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Radiology]]
[[Category:Radiology]]

Latest revision as of 00:40, 30 July 2020

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma MRI

CDC on VIPoma MRI

VIPoma MRI in the news

Blogs on VIPoma MRI

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI.

MRI

References

  1. Sofka, Carolyn M.; Semelka, Richard C.; Marcos, Hani B.; Woosley, John T. (1997). "MR Imaging of metastatic pancreatic VIPoma". Magnetic Resonance Imaging. 15 (10): 1205–1208. doi:10.1016/S0730-725X(97)00201-4. ISSN 0730-725X.
  2. Reidy-Lagunes, Diane L.; Gollub, Marc J.; Saltz, Leonard B. (2011). "Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?". Journal of Clinical Oncology. 29 (3): e74–e75. doi:10.1200/JCO.2010.32.8559. ISSN 0732-183X.


Template:WikiDoc Sources